Rexin-G Returns to The Big Apple: Clinical Trials for Pancreatic Cancer and Breast Cancer Open in Manhattan
środa, październik 29th, 2008SAN MARINO, Calif., Oct. 29 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation announced today the expansion of clinical trials using intravenous Rexin-G for pancreatic cancer and breast cancer in Manhattan, New York. Rexin-G is the world’s first tumor-targeted genetic medicine that is designed to seek out and destroy both primary tumors and metastatic cancers that have spread throughout the body. Clinical data from on-going studies in Los Angeles, California, indicating dose-dependent tumor control rates and survival benefits with no major toxicity in Rexin-G-treated patients prompted the extension of these clinical trials to the East Coast.
Rexin-G has gained orphan drug status from the U.S. FDA for three clinical indications: pancreatic cancer, osteosarcoma and soft tissue sarcoma.
The New York clinical trials will be conducted at the Bruckner Oncology Center in Manhattan, New York with Howard W. Bruckner, M.D. as the Principal Investigator. Dr. Bruckner is a board certified medical oncologist who trained [...]
Original post by WP-AutoBlog Import